Teva Nefazadone Statement

Teva has updated the FDA that we expect Nefazodone to return to the market in the fourth quarter of this year. In the interest of patients, Teva originally alerted the US FDA – and Wholesalers, Distributors and Pharmacies – in the summer of 2020 about a potential shortage of Nefazodone. We have been working diligently since that time and we are pleased to be able to confirm that we anticipate the product will return shortly. Until the product is available, patients should continue to speak with their physician about an alternative treatment that is right for them.

Share this article: